Dashboard
Manage Tickers

INCYINCYTE CORP

Nasdaq incyte.com


$ 64.36 $ 1.12 (1.77 %)    

Tuesday, 20-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 64.38
$ 63.13
$ 64.33 x 100
$ 64.38 x 300
$ 63.13 - $ 64.75
$ 50.27 - $ 70.36
1,942,912
na
14.05B
$ 0.53
$ 144.37
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-13-2024 12-31-2023 10-K
4 10-31-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-02-2023 03-31-2023 10-Q
7 02-07-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-08-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-09-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-13-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 07-30-2019 06-30-2019 10-Q
22 04-30-2019 03-31-2019 10-Q
23 02-14-2019 12-31-2018 10-K
24 10-30-2018 09-30-2018 10-Q
25 07-31-2018 06-30-2018 10-Q
26 05-01-2018 03-31-2018 10-Q
27 02-15-2018 12-31-2017 10-K
28 10-31-2017 09-30-2017 10-Q
29 08-01-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 02-14-2017 12-31-2016 10-K
32 11-01-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-12-2016 12-31-2015 10-K
36 11-03-2015 09-30-2015 10-Q
37 08-04-2015 06-30-2015 10-Q
38 04-30-2015 03-31-2015 10-Q
39 02-17-2015 12-31-2014 10-K
40 10-30-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

incyte-seeks-expanded-fda-approval-for-lymphoma-drug-after-releasing-promising-topline-data-from-late-stage-study
Incyte Seeks Expanded FDA Approval For Lym...
08/16/2024 13:29:34

Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in ...

incyte-announces-topline-results-from-study-of-tafasitamab-met-its-primary-endpoint-of-progression-free-survival-in-relapsed-or-refractory-follicular-lymphoma-the-secondary-endpoint-of-pfs-results-by-blinded-independent-review-are-consistent-with-investigator-based-pfs-results-no-new-safety-signals-with-tafasitamab-were-observed
Incyte Announces Topline Results From Stud...
08/15/2024 20:34:33

- Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®) or placebo in combination with lenalidomide...

analyst-expectations-for-incytes-future
Analyst Expectations For Incyte's Future
08/15/2024 20:01:41

fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-complication
FDA Approves Incyte/Syndax Partnered Drug ...
08/15/2024 14:11:20

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-67
RBC Capital Maintains Sector Perform on In...
08/15/2024 14:02:59

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $66...

Core News & Articles
Incyte, Syndax Secure FDA Approval For Nik...
08/14/2024 21:55:48

FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...

fda-approves-axatilimab-csfr-for-treatment-of-chronic-graft-versus-host-disease
FDA Approves Axatilimab-CSFR For Treatment...
08/14/2024 19:07:04

- Reuters 

deutsche-bank-maintains-hold-on-incyte-raises-price-target-to-60
Deutsche Bank Maintains Hold on Incyte, Ra...
08/01/2024 17:59:06

Deutsche Bank analyst James Shin maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $55 to $60.

citigroup-maintains-buy-on-incyte-raises-price-target-to-88
Citigroup Maintains Buy on Incyte, Raises ...
07/31/2024 19:33:54

Citigroup analyst David Lebowitz maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $80 to $88.

after-reporting-five-patient-deaths-data-committee-recommends-macrogenics-halt-prostate-cancer-trial
After Reporting Five Patient Deaths, Data ...
07/31/2024 17:45:20

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 202...

jp-morgan-maintains-neutral-on-incyte-raises-price-target-to-61
JP Morgan Maintains Neutral on Incyte, Rai...
07/31/2024 16:47:57

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $59 to $61.

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-66
RBC Capital Maintains Sector Perform on In...
07/31/2024 14:50:29

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $61...

b-of-a-securities-maintains-neutral-on-incyte-raises-price-target-to-66
B of A Securities Maintains Neutral on Inc...
07/31/2024 11:13:38

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $62 to...

Core News & Articles
MacroGenics Achieves $100M In Milestones R...
07/30/2024 20:19:14

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializ...

incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-guidance
Incyte's Q2 Earnings: Wider Than Expected ...
07/30/2024 16:57:28

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 5...

incyte-shares-are-trading-higher-after-the-company-beat-q2-revenue-estimates-and-raised-the-bottom-end-of-its-2024-jakafi-net-product-revenue-forecast
Incyte shares are trading higher after the...
07/30/2024 12:55:24

incyte-forecasts-2024-jakafi-net-product-revenue-of-271b-275b-versus-prior-guidance-of-269b-275b
Incyte Forecasts 2024 Jakafi Net Product R...
07/30/2024 11:11:03

2024 Financial Guidance Incyte is raising the low end of its full year 2024 Jakafi revenue guidance as well as updating its fu...

incyte-q2-2024-adj-eps-182-misses-155-estimate-sales-1044b-beat-1026b-estimate
Incyte Q2 2024 Adj. EPS $(1.82) Misses $(1...
07/30/2024 11:03:09

analyst-ratings-for-incyte
Analyst Ratings For Incyte
07/26/2024 17:00:41

oppenheimer-maintains-outperform-on-incyte-lowers-price-target-to-81
Oppenheimer Maintains Outperform on Incyte...
07/26/2024 16:58:53

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $84 to $81.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION